← The Library Research Portal →

Insulin/IGF-1 Signaling & Longevity

Abstract

The insulin/insulin-like growth factor-1 (IIS) signaling pathway represents the most evolutionarily conserved mechanism regulating lifespan across species, from nematodes to mammals. Since the landmark discovery of the daf-2 mutation in C. elegans by Cynthia Kenyon in 1993, which doubled worm lifespan, the IIS pathway has emerged as a master regulator of aging, metabolism, and stress resistance. This comprehensive review examines the molecular architecture of the IIS pathway, its downstream effectors including FOXO transcription factors, the growth hormone/IGF-1 axis in mammals, evidence from long-lived mutant mice and human populations with exceptional longevity, the complex relationship between insulin sensitivity and aging, cross-talk with nutrient-sensing pathways like mTOR and AMPK, and the fundamental tradeoff between anabolic growth and lifespan extension. Understanding this pathway has profound implications for interventions ranging from caloric restriction to pharmacological modulation of growth hormone signaling.

Introduction: The Most Conserved Aging Pathway

Among the numerous biological pathways that influence aging, the insulin and insulin-like growth factor-1 (IGF-1) signaling (IIS) pathway stands out for its remarkable evolutionary conservation and profound impact on lifespan. From yeast to worms, flies to mice, and potentially humans, reduced activity of this pathway consistently extends lifespan and delays age-related pathology. This conservation suggests that the IIS pathway represents a fundamental mechanism by which organisms coordinate growth, metabolism, reproduction, and longevity in response to nutrient availability.

The IIS pathway's role in aging sits at the intersection of multiple biological processes that define the hallmarks of aging. It regulates nutrient sensing, metabolic homeostasis, stress resistance, cellular maintenance, and the balance between growth and longevity. Understanding this pathway provides insight into how evolution has shaped aging and how we might intervene to extend healthy lifespan.

This review examines the IIS pathway from molecular mechanisms to organismal physiology, from invertebrate models to human populations, and from basic biology to therapeutic potential. We will see how a simple genetic mutation in a tiny worm opened the door to understanding one of biology's most fundamental tradeoffs: the choice between growing fast and living long.

The Insulin/IGF-1 Signaling Pathway: Molecular Architecture

Receptor Tyrosine Kinases

The IIS pathway begins at the cell surface with receptor tyrosine kinases (RTKs) that bind insulin and IGF-1. In mammals, this includes the insulin receptor (IR) and the IGF-1 receptor (IGF-1R), both of which are structurally similar transmembrane proteins. When insulin or IGF-1 binds to these receptors, they undergo conformational changes that trigger their intrinsic tyrosine kinase activity, leading to autophosphorylation of tyrosine residues on the intracellular domain.

This autophosphorylation creates docking sites for adaptor proteins, most notably the insulin receptor substrate (IRS) family of proteins. IRS proteins become phosphorylated on tyrosine residues, creating additional docking sites that propagate the signal downstream. This cascade amplification is a hallmark of growth factor signaling, allowing a small amount of extracellular hormone to trigger substantial intracellular responses.

The PI3K/AKT Cascade

The primary signaling pathway activated by IRS proteins involves phosphatidylinositol 3-kinase (PI3K). When PI3K binds to phosphorylated IRS proteins, it becomes activated and phosphorylates the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). This lipid second messenger recruits proteins containing pleckstrin homology (PH) domains to the plasma membrane, including the serine/threonine kinase AKT (also known as protein kinase B or PKB).

AKT is activated through phosphorylation by two kinases: phosphoinositide-dependent kinase 1 (PDK1), which phosphorylates AKT at threonine 308, and mammalian target of rapamycin complex 2 (mTORC2), which phosphorylates AKT at serine 473. Fully activated AKT is one of the most important nodes in cellular signaling, phosphorylating dozens of substrates that regulate metabolism, growth, survival, and longevity.

Critical downstream substrates of AKT include:

Negative Regulation: PTEN and Feedback Loops

The IIS pathway is tightly regulated by negative feedback mechanisms. The lipid phosphatase PTEN (phosphatase and tensin homolog) dephosphorylates PIP3 back to PIP2, directly antagonizing PI3K activity. PTEN is one of the most frequently mutated tumor suppressors in human cancer, highlighting the importance of restraining PI3K/AKT signaling for normal cellular homeostasis.

Additionally, the pathway contains multiple feedback loops. Activation of mTORC1 and its downstream target S6K1 leads to phosphorylation of serine residues on IRS proteins, which suppresses PI3K activation and creates negative feedback that limits pathway activity. This feedback mechanism may explain some of the complexities observed when trying to manipulate the IIS pathway pharmacologically.

The DAF-2 Discovery: A Paradigm Shift in Aging Research

Kenyon 1993: Doubling Lifespan with a Single Gene

In 1993, Cynthia Kenyon and colleagues published a landmark paper that fundamentally changed how scientists think about aging. Working with the nematode Caenorhabditis elegans, they discovered that mutations in a single gene, daf-2, could double the lifespan of these worms. This was revolutionary because it demonstrated that aging was not simply the inevitable accumulation of damage, but rather a regulated process that could be controlled by specific genes.

The daf-2 gene encodes an insulin/IGF-1 receptor ortholog, meaning it combines functions of both the insulin receptor and IGF-1 receptor found in mammals. When daf-2 activity is reduced through mutation, worms live approximately twice as long as normal and remain active and youthful-looking for much of this extended lifespan. Critically, this lifespan extension is not merely a prolongation of frailty, but represents a genuine slowing of the aging process itself.

Since this discovery, over 1,000 papers on daf-2 have been published, making it one of the most studied genes in C. elegans. The finding sparked an explosion of research into the genetic control of aging and established C. elegans as a premier model organism for longevity research.

DAF-16: The Master Downstream Effector

The mechanistic insight that made the daf-2 discovery so powerful came from genetic epistasis experiments showing that the longevity phenotype requires another gene: daf-16. When daf-16 is mutated, the lifespan extension from daf-2 mutations is completely abolished. This demonstrated that DAF-16 acts downstream of DAF-2 and is necessary for the longevity benefits of reduced insulin/IGF-1 signaling.

DAF-16 is the C. elegans ortholog of the FOXO (forkhead box O) family of transcription factors in mammals. When IIS pathway activity is high (abundant nutrients, active DAF-2 signaling), DAF-16/FOXO is phosphorylated by AKT and sequestered in the cytoplasm. When IIS activity is low (nutrient scarcity, reduced DAF-2 signaling), DAF-16/FOXO translocates to the nucleus where it activates transcription of hundreds of genes involved in stress resistance, metabolism, and longevity.

Conservation Across Evolution

The profound conservation of the IIS pathway's role in aging became apparent as researchers identified similar mechanisms in other organisms. In Drosophila melanogaster (fruit flies), mutations in the insulin receptor substrate (IRS) homolog chico extend lifespan. In yeast, deletion of genes in the glucose-sensing pathway increases replicative lifespan. This conservation suggests that the link between insulin/IGF-1 signaling and longevity arose early in evolution and has been maintained across hundreds of millions of years.

This evolutionary conservation also suggests that the tradeoff between growth/reproduction and longevity is a fundamental feature of life. In environments where nutrients are abundant, organisms benefit from growing quickly and reproducing early, even if this accelerates aging. When nutrients are scarce, shifting resources from reproduction to somatic maintenance and stress resistance becomes advantageous, allowing the organism to survive until conditions improve.

FOXO Transcription Factors: Guardians of Longevity

The FOXO Family

In mammals, there are four FOXO family members: FOXO1, FOXO3, FOXO4, and FOXO6. These transcription factors share a conserved DNA-binding domain (the forkhead box) and are regulated by similar post-translational modifications, particularly phosphorylation by AKT. When phosphorylated, FOXO proteins bind to 14-3-3 chaperone proteins and are retained in the cytoplasm, preventing them from activating their target genes. When dephosphorylated (in conditions of low IIS activity), FOXO proteins enter the nucleus and bind to specific DNA sequences to activate transcription.

The importance of FOXO proteins extends far beyond longevity. They regulate glucose metabolism in the liver, adipose tissue development, muscle atrophy, immune function, and cellular senescence. This pleiotropy reflects the central role of FOXO proteins in coordinating cellular responses to nutrient availability and metabolic stress.

FOXO Target Genes and Longevity Programs

FOXO transcription factors activate expression of hundreds of genes that promote stress resistance and cellular maintenance. These include:

This transcriptional program essentially shifts cells from a growth mode to a maintenance and survival mode. Resources are redirected from building new biomass to maintaining existing structures, repairing damage, and withstanding stress. This shift is thought to be a key mechanism by which reduced IIS extends lifespan.

FOXO3: The Human Longevity Gene

Among the FOXO family members, FOXO3 has emerged as particularly important for human longevity. Multiple studies have identified genetic variants in the FOXO3 gene that are consistently associated with exceptional longevity across diverse human populations. FOXO3 is one of only two genes (along with APOE) for which genetic polymorphisms have exhibited consistent associations with longevity in populations worldwide, including Japanese, European, American, and Chinese cohorts.

The longevity-associated FOXO3 single nucleotide polymorphisms (SNPs) include rs2764264, rs13217795, rs2802292, rs12206094, and rs4946935. Research has shown that these variants are intronic and not linked to coding SNPs, suggesting they affect FOXO3 expression levels rather than protein structure. Indeed, longevity-associated alleles are linked to higher FOXO3 mRNA expression in various human tissues.

A study of 1,762 German centenarians and nonagenarians found that FOXO3A polymorphisms were strongly associated with the ability to reach exceptional old age, with the association substantially stronger in centenarians than in nonagenarians. This dose-response relationship supports a causal role for FOXO3 in human longevity.

Recent research from 2024 examining Okinawan populations identified novel protective effects of the FOXO3 longevity genotype on cellular aging mechanisms, including improved mitochondrial function and reduced oxidative stress. This provides mechanistic insight into how FOXO3 variants may promote longevity at the cellular level.

FOXO4 and Senescent Cells

FOXO4 has gained attention for its specific role in maintaining senescent cell viability. Senescent cells are cells that have permanently stopped dividing but remain metabolically active, secreting inflammatory factors that contribute to aging and age-related disease. Research has shown that FOXO4 interacts with the tumor suppressor p53 in senescent cells, and that disrupting this interaction can selectively induce apoptosis in senescent cells while sparing normal cells.

The FOXO4-DRI (FOXO4-p53-disrupting retro-inverso) peptide was designed to interfere with the FOXO4-p53 interaction. Recent 2025 research demonstrates that FOXO4-DRI promotes p53 nuclear exclusion and cytoplasmic translocation in senescent cells, activating transcription-independent pro-apoptotic pathways. Treatment with FOXO4-DRI in aged mice resulted in improved kidney function, fur density, and physical fitness.

A February 2025 study showed that FOXO4-DRI induces apoptosis in keloid senescent fibroblasts by promoting nuclear exclusion of phosphorylated p53. This senolytic approach represents a novel application of FOXO biology to age-related pathology, potentially allowing removal of harmful senescent cells while preserving the longevity benefits of FOXO activation in healthy cells.

The Growth Hormone/IGF-1 Axis in Mammals

The Somatotropic Axis

In mammals, the insulin/IGF-1 signaling system is more complex than in invertebrates, involving separate hormones, receptors, and tissues. The growth hormone (GH)/IGF-1 axis, also called the somatotropic axis, is a key endocrine system that regulates growth, metabolism, and aging.

Growth hormone is secreted by the anterior pituitary gland in response to growth hormone-releasing hormone (GHRH) from the hypothalamus. GH travels through the bloodstream and acts on tissues throughout the body, with particularly important effects on the liver. In the liver, GH stimulates production and secretion of IGF-1, which then acts on target tissues via the IGF-1 receptor. Additionally, GH has direct effects on metabolism, including promoting lipolysis (fat breakdown) and antagonizing insulin action.

This endocrine cascade means that interventions affecting GH secretion, GH receptor signaling, or IGF-1 production can all influence the IIS pathway and potentially affect aging. The multi-tier organization also provides multiple points for regulatory control and evolutionary fine-tuning.

IGF-1: Local and Endocrine Actions

IGF-1 has both endocrine (circulating hormone) and paracrine/autocrine (local) actions. Circulating IGF-1 produced by the liver represents the majority of total IGF-1 in the body and provides systemic growth-promoting signals. However, many tissues also produce IGF-1 locally in response to GH or other stimuli. For example, muscle tissue produces IGF-1 in response to mechanical loading during exercise, which acts locally to promote muscle hypertrophy and repair.

This distinction between circulating and local IGF-1 may help explain some apparent paradoxes in the relationship between IGF-1 and longevity. High levels of circulating IGF-1 may promote aging and disease, while local IGF-1 production in response to beneficial stimuli like exercise may be health-promoting. The key may be context: chronic systemic elevation of IGF-1 versus acute, local increases in response to adaptive challenges.

Long-Lived Mutant Mice: Lessons from Dwarfism

Ames and Snell Dwarf Mice

If reduced insulin/IGF-1 signaling extends lifespan in worms and flies, does it work in mammals? This question was answered definitively by studies of naturally occurring dwarf mice. Both Ames dwarf mice and Snell dwarf mice carry mutations that affect pituitary development, resulting in deficiency of growth hormone, prolactin, and thyroid-stimulating hormone.

These mice are remarkably long-lived, with lifespans 40-60% longer than their normal littermates. They are also much smaller, weighing between one-third to one-half the body weight of normal animals. Despite their small size and hormonal deficiencies, these mice are healthy and exhibit delayed aging across multiple organ systems. They show reduced incidence of cancer, delayed immune system aging, better maintained connective tissue, and delayed pathological changes in joints.

The mechanism of longevity in these mice appears to be primarily related to IGF-1 deficiency. The congenital absence of GH-producing cells in the pituitary leads to lack of GH in circulation and thus to profound IGF-1 deficiency. Research demonstrates that reduced IGF-1 signaling is the key to their longevity, providing strong evidence that findings from invertebrates translate to mammals.

Interestingly, these dwarf mice show enhanced insulin sensitivity despite their extended longevity. This challenges the notion that reduced insulin signaling per se is necessary for longevity, and suggests that the ratio between insulin and IGF-1 signaling, or tissue-specific effects, may be important.

Growth Hormone Receptor Knockout (GHRKO) Mice

While Ames and Snell dwarf mice have congenital hormone deficiencies, growth hormone receptor knockout (GHRKO) mice provide a more specific test of GH/IGF-1 axis involvement in longevity. GHRKO mice have a targeted deletion of the growth hormone receptor gene, making them unable to respond to GH. They are also dwarf and have very low IGF-1 levels, but they retain normal prolactin and thyroid hormone.

Female GHRKO mice show significantly extended longevity, with mean, median, and maximal lifespan increased compared to controls. They also exhibit remarkably low rates of cancer, resistance to diet-induced diabetes, and decreased levels of proapoptotic factors along with increased expression of genes involved in mitochondrial biogenesis. GHRKO mice hold the Methuselah Prize for the world's longest-lived laboratory mouse, validating their exceptional longevity phenotype.

Importantly, the longevity of GHRKO mice is robust across different environmental conditions. Even when housed at thermoneutral temperature (30°C) from weaning, which significantly improves their growth and metabolic profile, GHRKO mice maintain their lifespan advantage. This suggests their longevity is due to intrinsic features of reduced GH signaling rather than compensatory responses to metabolic stress.

The research with GHRKO mice demonstrates that specifically targeting the GH receptor is sufficient to extend mammalian lifespan, supporting the development of GH receptor antagonists as potential longevity interventions.

Human Laron Syndrome: A Natural Experiment

The Ecuadorian Cohort

Perhaps the most compelling evidence that reduced GH/IGF-1 signaling can benefit human health comes from studies of people with Laron syndrome. This rare genetic disorder is caused by mutations in the growth hormone receptor gene, making individuals unable to respond to GH. The phenotype is strikingly similar to GHRKO mice: severe short stature (adult height typically under 4 feet), very low IGF-1 levels, but normal or elevated GH levels.

The largest single population of individuals with Laron syndrome lives in remote villages in southern Ecuador, where Dr. Jaime Guevara-Aguirre has studied them for over 30 years. This cohort provided a unique opportunity to examine the long-term health consequences of severe IGF-1 deficiency in humans living in their natural environment rather than a research institution.

Protection from Cancer and Diabetes

The findings from the Ecuadorian cohort are remarkable. Over a 22-year observation period, only one case of cancer was observed among individuals with Laron syndrome, despite a high rate of obesity in the population. After treatment for ovarian cancer in 2008, this individual remained cancer-free. In contrast, cancer was common in their unaffected relatives living in the same environment.

Even more striking, none of the Laron syndrome individuals developed diabetes over the 22-year period, despite high rates of obesity that would normally confer substantial diabetes risk. Their unaffected relatives showed typical rates of type 2 diabetes. This protection occurs despite obesity because these individuals have dramatically enhanced insulin sensitivity.

The mechanism appears to involve both reduced IGF-1 signaling and improved insulin sensitivity. Research demonstrates that absent GH counter-regulation induces a decrease in insulin resistance, resulting in low but highly efficient insulin levels that properly handle metabolic substrates. The combination of low IGF-1 signaling, decreased insulin resistance, and efficient insulin concentrations provides a reasonable explanation for diminished incidence of diabetes and cancer.

Molecular Mechanisms of Protection

Laboratory studies using serum from Laron syndrome individuals have provided mechanistic insight into their disease protection. When cells are exposed to a DNA-damaging toxin, cells bathed in serum from Laron syndrome individuals suffered fewer DNA breaks than cells in normal serum. This suggests that low IGF-1 protects against oxidative DNA damage. When IGF-1 was artificially added to the Laron serum, the protection disappeared, confirming that IGF-1 deficiency was responsible for the effect.

This enhanced stress resistance at the cellular level parallels findings in long-lived dwarf mice and in C. elegans daf-2 mutants, suggesting a conserved mechanism whereby reduced IIS enhances cellular defenses against damage. The Laron syndrome studies demonstrate that these mechanisms operate in humans and can provide substantial protection against major age-related diseases.

IGF-1 Levels and Human Longevity: A Complex Relationship

Evidence from Centenarian Studies

If complete IGF-1 deficiency protects against cancer and diabetes, what about more moderate reductions in IGF-1 in the general population? Studies of centenarians and their offspring have provided important insights. Research in exceptionally long-lived individuals found that low IGF-1 levels predict survival. Females with IGF-1 levels below the median (≤ 96 ng/mL) had significantly longer survival compared to females with levels above the median. Interestingly, this survival advantage was not observed in males, suggesting possible sex-specific effects.

Studies of centenarians' offspring found that IGF-1 bioactivity (the ability of IGF-1 to activate its receptor) was significantly lower compared to age-matched controls. This suggests that the offspring of centenarians inherit a metabolic profile characterized by reduced growth signaling, which may contribute to their own enhanced longevity prospects.

Genome-wide association studies in nonagenarians have shown clear associations between genetic variants in insulin/IGF-1 pathway genes and human longevity. Women with genetic profiles suggesting decreased insulin/IGF-1 signaling activity exhibited longer survival in prospective studies.

The U-Shaped Curve Paradox

However, the relationship between IGF-1 and human longevity is more complex than "lower is better." Meta-analyses have found a U-shaped association between IGF-1 levels and mortality risk. Both very low and very high IGF-1 levels are associated with increased risk of premature death from all causes, cancer, and cardiovascular disease. The lowest mortality risk occurs around the 55th percentile of serum IGF-1 distribution.

This U-shaped curve presents a puzzle. If low IGF-1 is beneficial in animal models and in Laron syndrome, why do extremely low levels in the general elderly population associate with increased mortality? Several explanations have been proposed:

The emerging picture suggests that maintaining relatively low IGF-1 throughout most of adult life may be beneficial for longevity, but allowing IGF-1 to become excessively low in old age may be detrimental. Some experts recommend aiming to keep IGF-1 in the lower-normal range during midlife, then ensuring adequate protein intake in later life to prevent excessive IGF-1 decline.

Insulin Sensitivity, Insulin Resistance, and Aging

The Metabolic Syndrome Connection

While reduced IGF-1 signaling appears beneficial for longevity, the role of insulin itself is more nuanced. Insulin resistance — the impaired ability of tissues to respond to insulin — is a hallmark of aging and a core feature of metabolic syndrome. Insulin resistance impairs glucose disposal, resulting in compensatory increases in pancreatic insulin secretion and chronic hyperinsulinemia (elevated blood insulin levels).

Metabolic syndrome is characterized by abdominal adiposity, glucose intolerance, hypertriglyceridemia, low HDL cholesterol, and hypertension, all occurring in association with insulin resistance and hyperinsulinemia. This cluster of metabolic abnormalities dramatically increases risk of type 2 diabetes, cardiovascular disease, and premature mortality.

Hyperinsulinemia as a Driver of Aging

Mounting evidence suggests that hyperinsulinemia itself plays a causal role in age-related disease and mortality. Chronic elevation of insulin may promote aging through multiple mechanisms:

The distinction between insulin resistance at the tissue level and the systemic consequences of compensatory hyperinsulinemia is important. Long-lived dwarf mice show enhanced insulin sensitivity (tissues respond well to insulin) and low insulin levels. In contrast, metabolically unhealthy humans show insulin resistance (tissues respond poorly to insulin) and high insulin levels. The combination of high insulin and intact signaling capacity may be particularly problematic.

Exercise, Insulin Sensitivity, and Longevity

One of the most consistent findings in longevity research is that physical activity extends healthspan and lifespan. A key mechanism appears to be improved insulin sensitivity. Exercise increases glucose uptake into muscle through both insulin-dependent and insulin-independent mechanisms (via AMPK activation), improves mitochondrial function, and reduces chronic inflammation.

During skeletal muscle aging, mitochondrial dysfunction, intramyocellular lipid accumulation, increased inflammation, and oxidative stress occur, all of which impair insulin sensitivity. Regular exercise counteracts these changes, maintaining insulin sensitivity into old age and potentially extending lifespan by reducing hyperinsulinemia and its downstream consequences.

Cross-Talk with mTOR: Integrating Growth and Nutrient Signals

The PI3K/AKT/mTOR Axis

The insulin/IGF-1 signaling pathway does not operate in isolation. One of its most important connections is with the mechanistic target of rapamycin (mTOR) pathway, another master regulator of growth, metabolism, and aging. mTOR is a key focal point where signals from nutrients, growth factors, and energy status converge.

As described earlier, activated AKT phosphorylates and inhibits the TSC1/TSC2 complex, relieving its suppression of mTORC1. This means that insulin and IGF-1 are potent activators of mTORC1, the rapamycin-sensitive mTOR complex that promotes protein synthesis, ribosome biogenesis, and cell growth while inhibiting autophagy.

In skeletal muscle, IGF-1 stimulation triggers the PI3K/AKT/mTOR cascade, which is essential for muscle hypertrophy. The pathway phosphorylates downstream targets including p70S6 kinase (S6K) and 4E-BP1, both of which promote mRNA translation and protein synthesis. This anabolic signaling is critical for muscle growth and repair but may come at a cost to longevity when chronically activated.

Amino Acids: An Alternative Route to mTOR

Importantly, mTOR can be activated by signals other than insulin/IGF-1. Amino acids, particularly branched-chain amino acids (BCAAs) like leucine, can activate mTORC1 through a mechanism that is independent of growth factor receptors, PI3K, and AKT. Amino acids promote binding of mTOR to Rheb (Ras homolog enriched in brain), directly activating the complex.

This dual regulation — by growth factors through PI3K/AKT and by nutrients through amino acid sensing — allows mTOR to integrate information about both systemic growth signals (hormones) and local nutrient availability. The cell activates anabolic processes only when both signals indicate favorable conditions for growth.

Feedback Inhibition and Pathway Integration

The IIS-mTOR connection includes important feedback loops. Activation of mTORC1 and its downstream target S6K1 leads to phosphorylation of serine residues on IRS proteins, which inhibits their ability to activate PI3K. This creates negative feedback that limits the intensity and duration of insulin/IGF-1 signaling.

This feedback mechanism has important implications for chronic mTOR activation. Prolonged mTOR activation (as might occur with constant nutrient excess and high protein intake) can lead to insulin resistance through this feedback pathway. This may be one mechanism linking overnutrition with metabolic disease and accelerated aging.

Studies of caloric restriction show coordinated changes in both IIS and mTOR signaling across multiple tissues, with reductions in both pathways contributing to the longevity benefits of dietary restriction.

AMPK: The Opposing Force

Energy Sensing and Metabolic Opposition

If insulin/IGF-1 signaling represents the "grow and reproduce" mode, AMP-activated protein kinase (AMPK) represents the opposing "conserve and survive" mode. AMPK is activated by low energy status, specifically by increased ratios of AMP to ATP or ADP to ATP. When cellular energy is depleted — such as during exercise, fasting, or metabolic stress — AMPK activates to restore energy balance.

The insulin/IGF-1 pathway is activated when nutrients are available, promoting lipid, protein, and glycogen synthesis. In contrast, AMPK activation during nutrient scarcity inhibits these biosynthetic pathways and stimulates catabolic processes. AMPK switches off ATP-consuming pathways (fatty acid and cholesterol synthesis, protein synthesis) and switches on ATP-generating processes (glucose uptake, fatty acid oxidation, mitochondrial biogenesis).

Metabolic Balance and Aging

The balance between IIS/mTOR (anabolic) and AMPK (catabolic) signaling is thought to be a key determinant of aging rate. Adaptations to nutrient availability are largely coordinated by AMPK and mTORC1. During low-nutrient conditions, AMPK activation stimulates catabolic processes and inhibits anabolic ones, while mTORC1 activation under nutrient-replete conditions initiates anabolic processes like protein synthesis and proliferation.

Many longevity interventions activate AMPK while suppressing IIS and mTOR:

Interestingly, AMPK can phosphorylate the insulin receptor, promoting ligand-independent activation of insulin signaling in muscle. This creates a complex regulatory loop where AMPK activation during exercise can enhance insulin sensitivity even while opposing insulin's anabolic effects. This may help explain why exercise improves metabolic health despite activating pathways that oppose insulin signaling.

Caloric Restriction and the IIS Pathway

Dietary Restriction Mimics Genetic Longevity Mutations

Caloric restriction (CR) — reducing food intake without malnutrition — is one of the most robust interventions for extending lifespan across species. The connection between CR and the IIS pathway provides important mechanistic insight into how diet influences aging.

In rodents, caloric restriction suppresses circulating IGF-1 and insulin levels in proportion to the degree of restriction, increases insulin sensitivity, enhances stress resistance, and reduces cancer risk. The magnitude of IGF-1 reduction can be as much as 40% with severe CR, closely mimicking the hormonal profile of long-lived dwarf mice.

Genetic studies support a connection between CR and IIS. Targeted disruption of growth hormone receptor interferes with the beneficial effects of caloric restriction, suggesting that reduced GH/IGF-1 signaling is necessary for at least some of CR's longevity benefits. Similarly, some of the benefits of CR are lost in animals with mutations affecting insulin/IGF-1 signaling, supporting the idea that CR works partly through this pathway.

Protein Restriction and IGF-1

Interestingly, protein restriction appears to be particularly important for reducing IGF-1 levels. While severe caloric restriction without malnutrition did not always change IGF-1 levels in human studies, protein restriction specifically led to significantly lower total and free IGF-1 concentrations.

Long-term studies in humans show that protein restriction can reduce serum IGF-1 concentration by 20-30%, with effects sustained over years. This has led to interest in protein restriction or time-restricted eating as more sustainable alternatives to continuous caloric restriction for modulating IIS in humans.

Fasting and the IIS Pathway

Intermittent fasting and time-restricted eating produce acute and dramatic changes in IIS pathway activity. During fasting, insulin and IGF-1 levels decline, FOXO proteins enter the nucleus and activate stress resistance programs, autophagy is upregulated, and AMPK becomes activated. These metabolic shifts may contribute to the health benefits observed with various fasting regimens.

The evolutionary logic is clear: when food is scarce, organisms benefit from activating maintenance and repair processes, enhancing stress resistance, and mobilizing stored nutrients, all of which are triggered by reduced IIS. The modern challenge is that most humans never experience true nutrient scarcity, maintaining chronically activated IIS that may accelerate aging.

Pharmacological Approaches to IIS Modulation

Growth Hormone Receptor Antagonists

The most direct pharmacological approach to reducing IIS would be to block growth hormone signaling. Pegvisomant is a pegylated GH receptor antagonist approved for treating acromegaly (excess GH production). It consists of a mutated GH protein conjugated to polyethylene glycol, which prevents normal GH receptor activation.

Over the past 20 years, pegvisomant has proven safe and effective for treating GH excess, with longitudinal data supporting its long-term use. Treatment with pegvisomant decreases plasma IGF-1 levels while elevating blood GH concentrations (due to loss of feedback inhibition).

While pegvisomant is not currently used for longevity purposes in healthy individuals, the extensive safety data from acromegaly patients and the clear longevity benefits seen in GHRKO mice make GH receptor antagonism an attractive theoretical approach. However, concerns about effects on muscle mass, bone density, and metabolic health would need to be carefully evaluated.

Recent research from 2025 has developed new growth hormone receptor antagonists (GHA2 and GHA3) with dual activity against both human and mouse receptors, potentially enabling better translational research between rodent models and human applications.

Challenges and Considerations

Several challenges complicate pharmacological modulation of IIS for longevity:

These challenges suggest that lifestyle interventions (diet, exercise) that produce more nuanced and reversible changes in IIS may be preferable to chronic pharmacological suppression for most individuals.

The Anabolic-Longevity Tradeoff

Growth vs. Lifespan: An Evolutionary Perspective

One of the most fundamental insights from IIS research is the existence of a tradeoff between anabolic processes (growth, reproduction) and longevity. This tradeoff is not accidental but reflects an evolutionary optimization shaped by natural selection.

In most environments ancestral to modern organisms, extrinsic mortality from predation, starvation, disease, and accidents was high. Under these conditions, organisms that grew quickly, reproduced early, and invested heavily in offspring production left more descendants than organisms that grew slowly and prioritized somatic maintenance for a long life that would likely be cut short anyway.

The IIS pathway evolved as a key mediator of this life history strategy. When nutrients are abundant (high IIS activity), organisms invest in rapid growth and reproduction. When nutrients are scarce (low IIS activity), organisms shift to a maintenance mode, waiting for conditions to improve. This switch explains why reduced IIS extends lifespan: it triggers a program optimized for surviving periods of scarcity, which happens to slow aging as a side effect.

The Muscle Mass Dilemma

In modern humans, this evolutionary tradeoff creates a practical dilemma. IGF-1 is crucial for muscle protein synthesis and preventing sarcopenia (age-related muscle loss). Low IGF-1 levels in elderly individuals are associated with muscle wasting, frailty, and functional decline. Yet chronically high IGF-1 may accelerate aging and increase cancer risk.

The role of IGF-1 in muscle is complex. Exercise stimulates local IGF-1 production in muscle, which promotes hypertrophy and repair. This local, transient increase differs from chronic systemic elevation. Research on IGF-1 isoforms shows that different splice variants (IGF-1Ea vs. IGF-1Ec/MGF) have distinct effects on muscle growth and may have different implications for aging.

Muscle maintenance in aging requires a careful balance. Too little IGF-1 signaling leads to muscle wasting and frailty. Too much may accelerate aging systemically. The solution may involve strategies that promote local IGF-1 signaling in muscle (through resistance exercise) while keeping systemic IGF-1 in the lower-normal range (through moderate protein intake and avoiding chronic overnutrition).

Navigating the Tradeoff

Several strategies may help navigate the anabolic-longevity tradeoff:

The protein intake question exemplifies this dilemma. Higher protein intake stimulates IGF-1 and supports muscle mass, which is protective in old age. Lower protein intake reduces IGF-1 and may reduce cancer risk, which is more relevant in midlife. The optimal approach likely varies by age, activity level, and individual health status.

Integrating the Evidence: Implications for Human Longevity

What the Science Tells Us

After three decades of research following the daf-2 discovery, several conclusions about IIS and longevity are well-established:

  1. The IIS pathway is a conserved longevity regulator: Across species from worms to mice, reduced IIS consistently extends lifespan and improves healthspan
  2. FOXO transcription factors are key mediators: Many benefits of reduced IIS require FOXO-dependent transcription of stress resistance and maintenance genes
  3. The pathway integrates with other longevity mechanisms: IIS cross-talks with mTOR, AMPK, sirtuins, and autophagy to coordinate cellular responses to nutrients
  4. Human genetic evidence supports relevance: FOXO3 variants associated with longevity and Laron syndrome's disease protection demonstrate effects in humans
  5. Context and dosage matter: Extreme reduction in IIS (Laron syndrome) provides disease protection but comes with tradeoffs. Moderate reduction may offer a better risk-benefit balance for most people
  6. Age-dependent effects exist: The optimal level of IIS likely changes across the lifespan

Translating to Practice

For individuals interested in applying this knowledge, several evidence-based approaches can modulate IIS:

Open Questions and Future Directions

Despite remarkable progress, important questions remain:

Research continues to address these questions, with ongoing studies examining the effects of protein restriction in humans, the development of selective IIS modulators, and the integration of IIS research with other areas of aging biology.

Conclusion: A Master Regulator of Aging

The insulin/IGF-1 signaling pathway stands as one of the most important discoveries in aging biology. From Cynthia Kenyon's seminal work with C. elegans to ongoing studies in human centenarians, research has revealed a deeply conserved mechanism linking nutrient sensing, growth, and longevity. The pathway's evolutionary conservation suggests it represents a fundamental biological principle: organisms must balance the competing demands of growth and reproduction against somatic maintenance and longevity.

For aging researchers, the IIS pathway provides a tractable target for intervention. Whether through dietary restriction, exercise, or future pharmacological approaches, modulating this pathway offers a promising route to extending healthy human lifespan. The existence of long-lived mouse mutants and protected human populations demonstrates that reduced IIS can deliver substantial health benefits in mammals.

At the same time, the complexity of the IIS pathway — its tissue-specific effects, interactions with other pathways, and age-dependent optima — cautions against oversimplification. "Lower is better" may apply to IGF-1 in midlife, but the relationship is more nuanced in advanced age. Context, dosage, and timing all matter.

Perhaps most importantly, research on IIS exemplifies how understanding the evolution of aging can guide interventions. The IIS pathway is not a design flaw to be corrected, but rather an evolved adaptation that optimized fitness in ancestral environments. Modern interventions work by exploiting this evolutionary program, triggering survival responses that happen to slow aging when activated in contemporary settings.

As we continue to unravel the intricacies of insulin/IGF-1 signaling and its role in human aging, we move closer to practical interventions that can extend not just lifespan, but healthspan — the period of life spent in good health, free from the disabilities and diseases that currently characterize old age. The journey from a long-lived worm to interventions in humans has been remarkable, and the path forward promises even greater discoveries.

Related Topics